Chronic condition treatment solutions company Convatec has landed a pivotal clearance from the U.S. Food and Drug Administration for its InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The new system is in good company with Convatec’s other existing InnovaMatrix AC product, and together they represent a pioneering step forward for next-gen placental-derived medical devices. The commercially available PD wound management iteration, armed with the recent FDA green light, replaces the now-defunct human particulate placenta products that used to crowd the market.
“Convatec is always proud to bring healing innovations to patients with hard-to-heal wounds,” said Convatec’s David Shepherd, the President and Chief Operating Officer of Advanced Wound Care. “We're pleased to offer physicians this new particulate product that is the first of its kind. It gives physicians a new, important tool for healing hard-to-heal wounds, continuing our efforts to expand the InnovaMatrix platform as part of our 'forever caring' promise.”
Requiring zero preparation, tissue tracking, nor special storage, InnovaMatrix PD heretofore brings unachievable levels of quality control, reliability, and safety to a system with its own inherent biological advantages due to the use of placenta. Acting as a xenograft, it has been controlled for a variety of data-influencing factors such as genetic variability, lifestyle, and environmental factors including diet and activity levels. InnovaMatrix PD can treat traumatic lacerations, post-surgical incisions, diabetic foot ulcers, post-Mohs surgery wounds, and much more.
